Dr. Santosh Lumdas Saraf, MD

Dr. Saraf practices at University of Illinois Hospital in Chicago, Illinois, part of University of Illinois System.

Dr. Saraf's NPI, 1407890650, was assigned on June 16, 2006. Dr. Saraf graduated from Temple University School of Medicine in 2003. Dr. Saraf holds Illinois license 036114206.

Dr. Saraf's primary practice is University of Illinois Hospital, at 1740 West Taylor St Suite 1400, Chicago, IL 60612 in Cook County. The practice phone is (312) 996-3900.

Dr. Saraf's primary practice is University of Illinois Hospital in Chicago, Illinois, part of University of Illinois System. The medical group on file is University of Illinois Physicians Group (UIPG).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Saraf practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Saraf's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Saraf is licensed in Illinois.

CMS data shows 54 Medicare services from Dr. Saraf across 1 procedure code in 2024, all of them office visits, for 35 Medicare patients. Medicare paid $3,705 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 35 Medicare patients who saw Dr. Saraf in 2024. 69% of them have high blood pressure, and 49% have arthritis. Their average risk score is 4.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Saraf's median patient age at 45, with 61% women.

In 2024, Dr. Saraf wrote 590 Medicare Part D claims for 40 patients. 79% of them were for generic drugs. CMS names the drug for 432 of them, across 16 drugs with 11 or more claims each, at $116,263 in total drug cost. In 2023, CMS named 500 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Saraf for performance year 2024, reported as part of a group. Dr. Saraf accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 126 papers to Dr. Saraf, published from 2010 to 2025. 2021 was the busiest year, with 13. The most frequent topics are Anemia, Sickle Cell, Glomerular Filtration Rate and Renal Insufficiency, Chronic. Dr. Saraf has published most often in Am J Hematol. Dr. Saraf's most frequent co-authors are Victor R. Gordeuk, MD, Robert E. Molokie, MD and Roberto Ferreira P. Machado, MD.

Dmand AI links Dr. Saraf to 4 clinical trials, 2 of them phase 2 studies. Conditions studied include Sickle Cell Trait, Vaso-Occlusive Crises and Albuminuria. Pfizer sponsors the most, 2.

CMS Open Payments shows 175 general payments to Dr. Saraf from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 55% of the total. Global Blood Therapeutics, Inc. paid the most, $95,966. It also lists 8 research payments totaling $8,315 from 2021 to 2025.

Dr. Saraf graduated from Temple University School of Medicine in 2003.